Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0PO0L
|
|||
| Drug Name |
Retroviral vector-transduced autologous T cells to express CD22-specific CARs
|
|||
| Drug Type |
CAR T Cell Therapy
|
|||
| Indication | Diffuse large B-cell lymphoma [ICD-11: 2A81; ICD-10: C83.3; ICD-9: 200] | Phase 1 | [1] | |
| Follicular lymphoma [ICD-11: 2A80; ICD-9: 202] | Phase 1 | [1] | ||
| Mantle cell lymphoma [ICD-11: 2A85.5; ICD-10: C83.1] | Phase 1 | [1] | ||
| Company |
Xinqiao Hospital of Chongqing
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | B-cell receptor CD22 (CD22) | Target Info | CAR-T-Cell-Therapy | [1] |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| Hematopoietic cell lineage | ||||
| B cell receptor signaling pathway | ||||
| Panther Pathway | B cell activation | |||
| Pathway Interaction Database | BCR signaling pathway | |||
| Reactome | Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | |||
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | ||||
| WikiPathways | B Cell Receptor Signaling Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02721407) Anti-CD22 CAR-T Therapy for CD19-refractory or Resistant Lymphoma Patients | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.